Corticotropin
Who holds supplier records for Corticotropin? No organisation holds a current US Type II DMF or EU CEP for Corticotropin in the registers PharmaTek covers. A further 5 organisations have only historical (inactive) DMF filings.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Corticotropin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/corticotropin
Reading the evidence
- No current DMF or CEP on record
Only historical filings exist in the covered registers. Any of these organisations may or may not supply today; confirm directly.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Corticotropin expires 27 Oct 2043. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (0)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Corticotropin. Country is the organisation's recorded country, not necessarily the manufacturing site.
Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (5)
Organisations whose Type II DMFs for Corticotropin are no longer active. These show a past filing, not current supply.
Show all 5 historical records
- PENINSULA LABS INCInactive DMF 8597 · filed Jun 1990
- MERCK SHARP AND DOHME BVInactive DMF 4181 · filed Jun 1981
- FREDERIKSBERG CHEMICAL LABORATORIES LTDInactive DMF 1780 · filed Aug 1971
- FERRING ABInactive DMF 1064 · filed Jun 1967
- UNITED STATES PHARMACOPEIAInactive DMF 68 · filed Mar 1951
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Corticotropin). The latest listed patent expires 27 Oct 2043. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Corticotropin is a unknown active pharmaceutical ingredient (ChEMBL CHEMBL1201610).
Chemical identity
- IUPAC name
- (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
- Canonical SMILES
- C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N
- InChIKey
- IDLFZVILOHSSID-OVLDLUHVSA-N
- Synonyms
- Acth, Acthar, Acthar gel, Acthar gel (autoinjector), Adrenocorticotrophin, Adrenocorticotropic hormone, Adrenocorticotropin, Adrenomone, Corticotrophin, Corticotropin, Corticotropina, Corticotropin (acth)
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Adrenocorticotropic Hormone
- Chemical structure
- Adrenocorticotropic Hormone
Record history
PharmaTek records which organisations hold a current DMF or CEP for Corticotropin every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
What do the historical Corticotropin records mean?
5 organisations have only inactive Type II DMFs for Corticotropin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Corticotropin?
Yes. The latest patent listed for an approved US product containing Corticotropin expires 27 Oct 2043, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Corticotropin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Corticotropin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.